Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $0.74 and last traded at $0.74, with a volume of 2,670,534 shares traded. The stock had previously closed at $0.95.

The company has a market capitalization of $11.40 million, a P/E ratio of 6.7954 and a beta of 3.51. The stock has a 50 day moving average of $1.39 and a 200 day moving average of $1.47.

Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a return on equity of 4.26% and a net margin of 11.28%. On average, analysts expect that Eleven Biotherapeutics, Inc. will post ($1.75) EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Eleven Biotherapeutics by 17.4% during the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 30,600 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in Eleven Biotherapeutics during the second quarter worth $175,000. Finally, Spark Investment Management LLC bought a new stake in shares of Eleven Biotherapeutics in the 2nd quarter worth $148,000. Hedge funds and other institutional investors own 5.03% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Eleven Biotherapeutics, Inc. (EBIO) Sets New 12-Month Low at $0.74” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2017/11/01/eleven-biotherapeutics-inc-ebio-sets-new-12-month-low-at-0-74.html.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.